Cytiva Pipe dream to pipeline WP 3
AstraZeneca and Cellectis partner to advance cell and gene therapies
Cellectis will receive a $25m upfront payment and up to $220m in equity investment, along with potential milestone based and royalty payments.
Cellectis will receive a $25m upfront payment and up to $220m in equity investment, along with potential milestone based and royalty payments.